Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

• Kristi L. Berger ,

  * E-mail: kristi.berger@boehringer-ingelheim.com

  Affiliations Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America, Boehringer Ingelheim Ltd/Ltée, R&D, Laval, QC, Canada

  ⨯
• Christoph Sarrazin,

  Affiliation J.W. Goethe University Hospital, Frankfurt, Germany

  ⨯
• David R. Nelson,

  Affiliation Clinical and Translational Science Institute, University of Florida, Gainesville, FL, United States of America

  ⨯
• Joseph Scherer,

  Affiliation Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America

  ⨯
• Nanshi Sha,

  Affiliation Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America

  ⨯
• Martin Marquis,

  Affiliation Boehringer Ingelheim Ltd/Ltée, R&D, Laval, QC, Canada

  ⨯
• Alexandra Côté-Martin,

  Affiliations Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America, Boehringer Ingelheim Ltd/Ltée, R&D, Laval, QC, Canada

  ⨯
• Richard Vinisko,

  Affiliation Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America

  ⨯
• Jerry O. Stern,

  Affiliation Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America

  ⨯
• Federico J. Mensa,

  Affiliation Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States of America

  ⨯
• George Kukolj

  Affiliations Boehringer Ingelheim Ltd/Ltée, R&D, Laval, QC, Canada, Boehringer Ingelheim Ltd/Ltée, Burlington, ON, Canada

  ⨯